- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Legal Bay Provides Update on Talc, Depo-Provera, and Cartiva Litigation
Pre-settlement funding provider sees varying stages of mass tort cases
Published on Mar. 5, 2026
Got story updates? Submit your updates here. ›
Legal Bay LLC, a national pre-settlement funding company, has released its 2026 outlook on three major lawsuits it continues to monitor and fund: talc ovarian cancer litigation involving Johnson & Johnson, Depo-Provera brain tumor claims, and the emerging Cartiva toe implant lawsuits. The company reports steady demand for lawsuit funding as plaintiffs navigate prolonged court timelines, bellwether trials, and potential global settlements.
Why it matters
Mass tort litigation continues to evolve at different stages nationwide, and pre-settlement funding can provide financial stability for plaintiffs facing mounting medical bills, lost income, and daily living expenses while they pursue full and fair compensation.
The details
In the talc litigation, the cases have returned to traditional tort proceedings and settlement negotiations after multiple bankruptcy attempts by Johnson & Johnson were dismissed. Analysts suggest the company is now in a strong financial position to resolve outstanding liabilities. The Depo-Provera litigation is entering its middle phase, with coordinated proceedings advancing and bellwether trials expected to begin. The presiding judge has signaled that third-party litigation funding agreements may be subject to scrutiny as part of discovery proceedings. The Cartiva toe implant litigation represents an emerging area of focus, as the early-stage medical device mass tort presents heightened uncertainty.
- Talc litigation has reached a mature phase, with many in the industry believing 2026 may bring a meaningful global resolution.
- Depo-Provera bellwether trials are expected to begin, shaping the evidentiary and valuation landscape.
- Cartiva toe implant litigation is still in its early phases, with details continuing to develop.
The players
Legal Bay LLC
A nationally-recognized provider of pre-settlement funding and mass tort finance.
Johnson & Johnson
The company facing tens of thousands of talcum powder product liability lawsuits alleging ovarian cancer or mesothelioma.
Chris Janish
The CEO of Legal Bay.
What they’re saying
“Talc litigation has clearly reached a mature phase. With bankruptcy options exhausted and the company in a strong financial position, many in the industry believe 2026 may finally bring a meaningful global resolution. Plaintiffs, however, still face uncertainty and long timelines, and that's where responsible pre-settlement funding can help.”
— Chris Janish, CEO of Legal Bay
“We recognize that disclosure requirements are becoming a larger part of complex litigation. Legal Bay has invested in compliance infrastructure to ensure we operate transparently and within court guidelines. Where funding is appropriate and permissible, we will continue assisting qualified plaintiffs.”
— Chris Janish, CEO of Legal Bay
What’s next
The judge in the Depo-Provera case will decide whether to allow disclosure of third-party litigation funding agreements as part of discovery proceedings.
The takeaway
Pre-settlement funding can provide financial stability for plaintiffs navigating the complex and prolonged timelines of mass tort litigation, but providers must operate transparently and within evolving regulatory and judicial guidelines.
